It’s been a bruising week for the ASX healthcare sector, with three of its biggest names — CSL Limited (ASX:CSL), PRO MEDICUS LIMITED (ASX:PME) and Cochlear Ltd — all sold down sharply after delivering their latest numbers, helping to drive the ASX healthcare index down nearly 3% on Friday afternoon.
In isolation, none of the updates were catastrophic. But in a market increasingly sensitive to earnings misses, guidance nuance and valuation risk, even modest disappointments have been punished. The result: billions wiped from the sector’s market capitalisation in a matter of days.
CSL: Profit miss and leadership shock
CSL set the tone earlier in the week. The blood-products giant posted a softer-than-expected first half for FY26, alongside news of its CEO’s departure — a combination that unsettled investors already wary of margin pressure and restructuring impacts.
Revenue for the half slipped 4% to US$8.33 billion, undershooting consensus expectations. Underlying NPATA fell 7% to US$1.95 billion, while statutory net profit plunged 81% to US$401 million after roughly US$1.1 billion in impairments, largely tied to intangible assets in CSL Vifor and licensing and asset adjustments in Seqirus.
The interim dividend was held flat at 130 cents per share, slightly below expectations.
Importantly, management reaffirmed FY26 guidance, pointing to NPATA growth of 4–7% and revenue growth of 2–3%. But commentary flagged a softer second half for Seqirus due to influenza seasonality and ongoing pressure in Vifor from generic competition in iron products.
The market reaction has been severe. CSL shares are trading around $152, down nearly 16% over the past week and more than 40% over six months — levels not seen since 2018. For a stock long considered a defensive cornerstone of Australian portfolios, the shift in sentiment has been stark.
Pro Medicus: Strong growth, wrong moment
If CSL’s result was broadly weak, Pro Medicus delivered something more nuanced — solid underlying performance, but at the wrong time and valuation.
The imaging software group reported strong revenue growth and further margin expansion in the first half. Underlying EBITDA came in around $90 million, with EBIT margins lifting to 73% from 72% a year earlier. Yet earnings fell short of consensus forecasts, largely due to contract timing and cost growth.
That was enough to trigger a sharp repricing. Shares dropped more than 20% in a single session and are now down about 26% over five days, trading near $120 — almost 60% below their level six months ago.
Broker reactions were mixed but telling. Several retained positive or neutral recommendations while cutting price targets substantially, arguing that the sell-off reflects a de-rating of high-multiple healthcare and AI-linked names rather than structural deterioration in Pro Medicus’ business.
Still, the episode highlights the challenge facing premium-growth stocks. With valuations previously stretched and the broader market questioning AI-driven narratives, even modest earnings skew can prompt outsized moves.
Cochlear: Nexa delays weigh on first half
Cochlear’s half-year update followed a similar script: respectable numbers, but just below expectations — and a market quick to punish.
Revenue rose 1% to $1.18 billion, missing estimates, while underlying NPAT fell 9% to $194.8 million. Cochlear implant unit sales were slightly under consensus, and the interim dividend of 215 cents per share came in marginally below forecasts.
The company attributed the softer first half largely to extended registration and contracting timelines for its new Nexa system. Management expects a stronger second half as Nexa becomes more broadly available, alongside growth in services and improved momentum in its acoustics segment.
Guidance for FY26 underlying NPAT of $435 million–460 million was maintained, though commentary suggested results are likely to land towards the lower end due to first-half delays and foreign exchange headwinds.
Even so, the stock was marked down sharply, falling more than 17% in Friday afternoon trading and now sitting around $204, down roughly 35% over six months.
A sector repriced
The week’s results underscore a broader shift in how the market is treating healthcare.
For years, major players like CSL have commanded premium multiples based on consistent growth, global footprints and high margins. That premium now appears under review. Investors are less willing to look through short-term weakness, and more inclined to compress valuations at the first hint of earnings risk.
CSL, Pro Medicus and Cochlear have not abandoned guidance, and all three point to stronger second halves. But in the current environment, reassurance is not the same as reward.
For biotech and health investors, the message from this results season is clear: execution still matters — but so does timing, tone and expectation management.